- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07766213
Pain Phenotypes in Individuals With Multiple Sclerosis
Pain Phenotyping in Multiple Sclerosis Based on IASP Criteria
This observational cross-sectional study aims to determine chronic pain phenotypes in individuals with multiple sclerosis (MS) and to investigate the clinical characteristics associated with different pain phenotypes. Participants with MS and chronic pain will undergo a comprehensive clinical assessment to identify nociceptive, neuropathic, nociplastic, and mixed pain phenotypes. The assessment will include clinical history, pain characteristics and distribution, quantitative sensory testing, pain intensity, disease severity, fatigue, health-related quality of life, and pain catastrophizing. The clinical characteristics of participants with different pain phenotypes will subsequently be compared.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Multiple sclerosis (MS) is a chronic, progressive, autoimmune disease of the central nervous system characterized by inflammatory demyelination and axonal damage. Pain is common among individuals with MS and may substantially affect functioning and quality of life. Different pain mechanisms may coexist in individuals with MS; however, the contribution of nociceptive, neuropathic, nociplastic, and mixed pain phenotypes in this population remains insufficiently characterized.
This cross-sectional observational study will include individuals with a definite diagnosis of MS who experience chronic pain. Participants will undergo a comprehensive clinical assessment to determine their predominant pain phenotype. Pain phenotyping will incorporate clinical history, pain characteristics and distribution, hypersensitivity findings, comorbidities, and quantitative sensory testing.
Quantitative sensory testing will include static tactile mechanical detection, thermal perception, static mechanical allodynia, dynamic mechanical allodynia, and vibration perception. Testing will be performed under standardized environmental conditions and initially at the participant's most painful body region.
In addition to pain phenotyping, pain intensity, pain distribution, pain catastrophizing, fatigue, health-related quality of life, and MS disease severity will be evaluated. Clinical characteristics will subsequently be compared among participants with different pain phenotypes to investigate the potential clinical impact of pain mechanisms in individuals with MS.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Nisa TURUTGEN, Msc.
- Número de telefone: 1499 00902742651300
- E-mail: nisa.turutgen@ksbu.edu.tr
Locais de estudo
-
-
Turkiye
-
Kütahya, Turkiye, Turquia (Türkiye), 43100
- Recrutamento
- Kutahya Health Sciences University Physical Medicine and Rehabilitation Department
-
Contato:
- Ismail SARACOGLU, Head of Department
- Número de telefone: 1499 002742651300
- E-mail: ismail.saracoglu@ksbu.edu.tr
-
Investigador principal:
- Nisa TURUTGEN, Msc.
-
Investigador principal:
- Dursun CEYLAN, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Participants meeting the inclusion criteria will be taken for this cross-sectional study. Individuals with MS who apply to Kutahya Health Sciences University Hospital Physiotherapy Department will be screened for eligibility by their clinic physicians and will then be asked to participate in this study.
Descrição
Inclusion Criteria:
- Age 18 years or older
- Definite diagnosis of multiple sclerosis according to the McDonald criteria
- No MS relapse or high-dose steroid treatment within the previous 3 months
- Pain intensity ≥2 on the Numeric Rating Scale in at least one body region for at least 3 months
- Ability to read, understand, and communicate in Turkish
Exclusion Criteria:
- Pregnancy
- Severe psychiatric disorder and/or severe cognitive impairment confirmed by a neurologist or neuropsychiatrist
- Presence of a serious pathology or disease that may compromise the assessment process or affect clinical decision-making, including metastasis, cancer, untreated or unhealed fractures, neurological disorders other than multiple sclerosis, or a history of diabetes
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: CROSS_SECTIONAL
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Quantitative sensory test: static tactile mechanical threshold
Prazo: 10 minutes
|
Von Frey Monofilaments (2 gr- 26 gr) will be used assessment for the static tactile mechanical detection threshold. |
10 minutes
|
|
Quantitative sensory test: hot-cold pain threshold
Prazo: 5 minutes
|
Coins will be used for the hot-cold pain threshold. The cold sensing test will be done with a coin held at room temperature. The hot sensing test will be done in the form of a coin placed in the pocket and applied to the participant after waiting for 30 minutes. |
5 minutes
|
|
Quantitative sensory test: static mechanical allodynia
Prazo: 5 minutes
|
A digital algometer device (JTech) will be used for static mechanical allodynia (pressure pain threshold). In the device, the pain sensation will be tested by applying 4 kg of pressure to the participant. |
5 minutes
|
|
Quantitative sensory test: dynamic mechanical allodynia
Prazo: 5 minutes
|
A soft brush will be used for dynamic mechanical allodynia. The brush will be gently moved over the skin at a speed of 3-5 cm per second in a fixed direction over the patients primary painful area. |
5 minutes
|
|
Quantitative sensory test: vibration sense
Prazo: 5 minutes
|
128 Hz tuning fork will be used in vibration assessment. The device will be applied over the bony prominences in the painful area of the patient. |
5 minutes
|
|
Margolis Pain Diagram
Prazo: 1 minute
|
The Margolis Pain Diagram, consists of a dorsal and a ventral drawing body, is used to assess the location and distribution of the pain [20]. Participants will ask to point out the place where they experience pain during the preceding 4 weeks for at least 24 hours. |
1 minute
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Numeric Pain Rating Scale
Prazo: 1 minute
|
Pain intensity will be assessed using the 11-point Numeric Rating Scale (NRS). Participants will rate their pain intensity from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity. |
1 minute
|
|
Pain Catastrophizing Scale (PCS)
Prazo: 5 minutes
|
Pain catastrophizing will be assessed using the 13-item Pain Catastrophizing Scale (PCS). The scale evaluates three dimensions of pain catastrophizing: rumination, helplessness, and magnification. Each item is scored from 0 to 4, resulting in a total score ranging from 0 to 52. Higher scores indicate greater pain catastrophizing. |
5 minutes
|
|
Modified Fatigue Impact Scale (MFIS)
Prazo: 1 minute
|
Fatigue will be assessed using the Modified Fatigue Impact Scale (MFIS). The MFIS evaluates the perceived impact of fatigue on physical, cognitive, and psychosocial functioning. It consists of 21 items scored on a 5-point Likert scale from 0 to 4, resulting in a total score ranging from 0 to 84. Higher scores indicate a greater impact of fatigue on daily functioning. Physical, cognitive, and psychosocial subscale scores may also be calculated separately. |
1 minute
|
|
Health-Related Quality of Life
Prazo: 5 minutes
|
Health-related quality of life will be assessed using the Short Form-12 Health Survey (SF-12). The questionnaire consists of 12 items and provides physical and mental component scores. Higher scores indicate better health-related quality of life. |
5 minutes
|
|
Multiple Sclerosis Disease Severity
Prazo: 5 minutes
|
Multiple sclerosis-related neurological disability and disease severity will be assessed using the Expanded Disability Status Scale (EDSS). The EDSS evaluates neurological impairment and disability associated with MS, with higher scores indicating greater neurological disability. |
5 minutes
|
|
Overactive Bladder Questionnaire-V8 (OAB-V8)
Prazo: 5 minutes
|
Overactive bladder symptoms will be assessed using the Overactive Bladder Questionnaire-V8 (OAB-V8). The questionnaire consists of 8 items evaluating the degree of bother associated with symptoms such as urinary urgency, frequency, nocturia, and urge urinary incontinence. Higher total scores indicate greater symptom burden related to overactive bladder. |
5 minutes
|
|
Hospital Anxiety and Depression Scale (HADS)
Prazo: 5 minutes
|
Anxiety and depressive symptoms will be assessed using the Hospital Anxiety and Depression Scale (HADS). The scale consists of 14 items divided into two 7-item subscales: the Hospital Anxiety and Depression Scale-Anxiety (HADS-A) and the Hospital Anxiety and Depression Scale-Depression (HADS-D). Each item is scored from 0 to 3, resulting in subscale scores ranging from 0 to 21. Higher scores indicate greater anxiety or depressive symptom severity. |
5 minutes
|
|
Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
Prazo: 10 minutes
|
Cognitive function will be assessed using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), a standardized cognitive assessment battery developed for individuals with multiple sclerosis. The battery includes the Symbol Digit Modalities Test (SDMT) for information processing speed, the California Verbal Learning Test-Second Edition (CVLT-II) for verbal learning and memory, and the Brief Visuospatial Memory Test-Revised (BVMT-R) for visuospatial learning and memory. Test scores will be recorded separately, with higher scores generally indicating better cognitive performance. |
10 minutes
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Dor
- Manifestações Neurológicas
- Doenças do Sistema Nervoso
- Doenças Neuromusculares
- Doenças autoimunes
- Doenças do sistema imunológico
- Doenças do Sistema Nervoso Periférico
- Doenças Autoimunes Desmielinizantes, SNC
- Doenças Autoimunes do Sistema Nervoso
- Doenças Desmielinizantes
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Esclerose múltipla
- Dor crônica
- Neuralgia
- Dor Nociplásica
Outros números de identificação do estudo
- NisaPHD
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .